BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fonseca F, Torrens M. Pharmacogenetics of Methadone Response. Mol Diagn Ther 2018;22:57-78. [DOI: 10.1007/s40291-017-0311-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Butler SH. Some controversies related to questionable clinical uses of methadone for chronic non-cancer pain and in palliative care. Scand J Pain 2021;21:421-5. [PMID: 33725755 DOI: 10.1515/sjpain-2020-0178] [Reference Citation Analysis]
2 Cozzoli D, Daponte A, De Fazio S, Ariano V, Quaranta MR, Leone V, Ostuni A, Casanova M, Catacchio CR, Ventura M, Montinaro F. Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies. Biomedicines 2021;9:1799. [PMID: 34944615 DOI: 10.3390/biomedicines9121799] [Reference Citation Analysis]
3 Noble F, Marie N. Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine. Front Psychiatry 2018;9:742. [PMID: 30713510 DOI: 10.3389/fpsyt.2018.00742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
4 Vorspan F, Marie-Claire C, Bellivier F, Bloch V. Biomarkers to predict staging and treatment response in opioid dependence: A narrative review. Drug Dev Res 2021;82:668-77. [PMID: 33416203 DOI: 10.1002/ddr.21789] [Reference Citation Analysis]
5 Chawar C, Hillmer A, Sanger S, D'Elia A, Panesar B, Guan L, Xie DX, Bansal N, Abdullah A, Kapczinski F, Pare G, Thabane L, Samaan Z. A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. Addict Sci Clin Pract 2021;16:70. [PMID: 34838141 DOI: 10.1186/s13722-021-00278-y] [Reference Citation Analysis]
6 Corli O, Damia G, Galli F, Verrastro C, Broggini M. Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients. Cancer Manag Res 2019;11:10337-44. [PMID: 31849523 DOI: 10.2147/CMAR.S211818] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Kaski SW, Brooks S, Wen S, Haut MW, Siderovski DP, Berry JH, Lander LR, Setola V. Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia. J Opioid Manag 2019;15:103-9. [PMID: 31057342 DOI: 10.5055/jom.2019.0491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xie X, Gu J, Zhuang D, Chen X, Zhou Y, Shen W, Li L, Liu Y, Xu W, Hong Q, Chen W, Zhou W, Liu H. Association study of genetic polymorphisms in GABRD with treatment response and dose in methadone maintenance treatment. Per Med 2021;18:423-30. [PMID: 34160285 DOI: 10.2217/pme-2021-0063] [Reference Citation Analysis]
9 Abijo T, Blum K, Gondré-Lewis MC. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. Curr Neuropharmacol 2020;18:578-95. [PMID: 31744450 DOI: 10.2174/1570159X17666191118125702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Victorri-Vigneau C, Verstuyft C, Bouquié R, Laforgue EJ, Hardouin JB, Leboucher J, Le Geay B, Dano C, Challet-Bouju G, Grall-Bronnec M. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Br J Clin Pharmacol 2019;85:1538-43. [PMID: 30907440 DOI: 10.1111/bcp.13936] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
11 Vatter T, Klumpp L, Ganser K, Stransky N, Zips D, Eckert F, Huber SM. Against Repurposing Methadone for Glioblastoma Therapy. Biomolecules 2020;10:E917. [PMID: 32560384 DOI: 10.3390/biom10060917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]